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The role of cholesterol in Alzheimer’s disease (AD) has been linked to the generation of toxic amyloid  peptides (A). Using genetic
mouse models of cholesterol loading, we examined whether mitochondrial cholesterol regulates A neurotoxicity and AD pathology.
Isolated mitochondria from brain or cortical neurons of transgenic mice overexpressing SREBP-2 (sterol regulatory element binding
protein 2) or NPC1 (Niemann-Pick type C1) knock-out mice exhibited mitochondrial cholesterol accumulation, mitochondrial glutathi-
one (mGSH) depletion and increased susceptibility to A1–42-induced oxidative stress and release of apoptogenic proteins. Similar
findings were observed in pharmacologically GSH-restricted rat brain mitochondria, while selective mGSH depletion sensitized human
neuronal and glial cell lines to A1–42-mediated cell death. Intracerebroventricular human A delivery colocalized with mitochondria
resulting in oxidative stress, neuroinflammation and neuronal damage that were enhanced in Tg-SREBP-2 mice and prevented upon
mGSH recovery by GSH ethyl ester coinfusion, with a similar protection observed by intraperitoneal administration of GSH ethyl ester.
Finally, APP/PS1 (amyloid precursor protein/presenilin 1) mice, a transgenic AD mouse model, exhibited mitochondrial cholesterol
loading andmGSH depletion. Thus, mitochondrial cholesterol accumulation emerges as a novel pathogenic factor in AD bymodulating
A toxicity viamGSH regulation; strategies boosting the particular pool ofmGSHmay be of relevance to slow down disease progression.
Introduction
Alzheimer’s disease (AD) is a major neurodegenerative disorder
characterized by progressive memory loss and cognitive impair-
ment due to neuronal death mainly in cortex and hippocampus
(Mattson, 2004; Zlokovic, 2005; Selkoe, 2007). Given the lack of
effective therapy and its association with aging, AD is one of the
most pressing health challenges worldwide. Although AD patho-
genesis is still unknown, accumulation or faulty brain clearance
of neurotoxic amyloid  peptides (A) is thought to play a key
role in AD (Tanzi et al., 2004;Walsh and Selkoe, 2004; Deane and
Zlokovic, 2007;Haass and Selkoe, 2007). Indeed, recent data have
showed that A dimers isolated directly from AD brains impair
synaptic plasticity and memory (Shankar et al., 2008).
In addition to aging, epidemiological observations identified
hypercholesterolemia in mid-life as a major risk factor for AD
(Notkola et al., 1998; Wolozin et al., 2000; Anstey et al., 2008).
Despite that studies examining statin usage have producedmixed
conclusions, the epidemiological evidence linking cholesterol to
AD has been supported by in vivo (Scho¨nknecht et al., 2002;
Bandaru et al., 2007) and in vitro studies (Fassbender et al., 2001;
Kalvodova et al., 2005; Osenkowski et al., 2008), indicating that
membrane cholesterol promotes the amyloidogenic processing
of themembrane bound amyloid precursor protein (APP) by the
-secretase BACE1 (-site APP-cleaving enzyme 1) and
-secretase to generate toxic A.
Well before plaques are observed, intracellular aggregates of
A develop early in AD transgenic mice, which congregate in
synaptic compartments and correlate with cognitive impairment
(Oddo et al., 2003). Current evidence indicates the targeting of
A to intracellular sites, most notably mitochondria, causing ox-
idative stress,mitochondrial dysfunction and cell death (Casley et
al., 2002; Lustbader et al., 2004; Caspersen et al., 2005; Lin and
Beal, 2006; Manczak et al., 2006).
Mitochondria do not synthesize glutathione (GSH) de novo
and mitochondrial GSH (mGSH) originates by the transport of
cytosol GSH into mitochondria by a specific carrier whose sensi-
tivity to changes in membrane fluidity has been previously char-
acterized (for review, see Fernandez-Checa andKaplowitz, 2005).
Cholesterol-mediated changes in membrane dynamics impairs
themitochondrial transport of GSH, resulting in the depletion of
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mGSH, a critical antioxidant defense that determines the suscep-
tibility to stimuli that inducemitochondrial oxidative stress, such
as TNF-, Fas, or hypoxia (Colell et al., 1997; Marí et al., 2006,
2008; Lluis et al., 2007). However, the specific role of mGSH in
the regulation of A toxicity has not been previously described.
Thus, we addressed whether mitochondrial cholesterol accumu-
lation modulates A neurotoxicity and AD pathology, using ge-
netic models of cholesterol loading, namely, transgenic mice
overexpressing SREBP-2 and NPC1/ mice (Yu et al., 2005).
Overall, these findings expand the role of cholesterol in AD, in-
dicating that in addition to fostering A production, mitochon-
drial cholesterol loading determines A neurotoxicity and AD-
like pathology via mGSH depletion. Although total GSH
depletion and alteredGSH redox cycle have been described inAD
(Boyd-Kimball et al., 2005; Resende et al., 2008), the fact that the
pool of mGSH rather than cytosol GSH determines A suscepti-
bility implies that efforts should be directed to specifically replen-
ishmGSH to slow down disease progression, using strategies that
bypass the block ofGSH transport intomitochondria imposed by
cholesterol deposition.
Materials andMethods
Tg-SREBP-2, NPC1/ and Tg-APP/PS1 mice. Breeding pairs of B6;SJL-
Tg(rPEPCKSREBF2)788Reh/J, BALB/cJ NPC1NIH and B6C3-
Tg(APPswe,PSEN1dE9)85Dbo/J mice were obtained from The Jackson
Laboratory. At the time of weaning (21 d), mice were genetically identi-
fied by PCR using DNA prepared from tail-tips and following the geno-
typing protocols provided by the supplier. All procedures involving ani-
mals and their care were approved by the ethics committee of the
University of Barcelona and were conducted in accordance with institu-
tional guidelines in compliance with national and international laws and
policies.
Cell cultures. SH-SY5Y human neuroblastoma (ECACC) and C6 rat
glioma cell lines were grown in Ham’s F12 (Sigma) containing 10% FBS
and 2mM glutamine. U118 human glioma and neurogliomaH4 cell lines
were maintained in DMEM medium (Invitrogen) supplemented with
10% FBS and 2mM glutamine. Mice neuron-rich cultures were obtained
from the cerebral cortex of embryos (day 16) using standard techniques.
Dissociated cells were suspended in Neurobasal medium (Invitrogen)
with 2.5% (v/v) B27 supplement (Invitrogen), 0.5 mM glutamine, and
10% FBS and plated onto poly-D-lysine coated plates at a cell density of
2  105/cm2. The culture medium was changed 3 h after plating and
every other day thereafter. After 24 h in vitro, the culture medium was
replacedwith serum-freemedium. Experiments were performed at 6 d in
vitro (DIV). The cellular composition of the cultures was evaluated at this
time by immunohistochemical analysis using antibodies to neuron- and
glial-specific markers and was found to consist of95% neurons.
Mitochondrial isolation. Cerebral cortices were isolated and homoge-
nized in 210 mM Mannitol, 60 mM Sucrose, 10 mM KCl, 10 mM Sodium
succinate, 1 mM ADP, 0.25 mM DTT, 0.1 mM EGTA, 10 mM HEPES, pH
7.4. The homogenates were centrifuged at 600  g for 10 min, with the
resulting supernatant being centrifuged at 10,300  g for 15 min. The
resulting pellet was suspended in 2 ml, loaded onto 8 ml of 30% (v/v)
Percoll gradient and centrifuged at 95,000 g for 30min. Themitochon-
drial pellet was then rinsed twice by centrifuging 15 min at 7000  g.
Cortical neurons were fractionated into cytosol and mitochondria by
digitonin permeabilization followed by oil gradient centrifugation as de-
scribed previously in detail (Fernandez-Checa et al., 1987).
GSH and cholesterol measurements. GSH levels in homogenates or cy-
tosol and mitochondria were analyzed by the recycling method (Tietze,
1969). For total cholesterol determination, 10 mg of protein was sapon-
ified with alcoholic KOH in a 60°C heating block for 30 min. After the
mixture had cooled, 10 ml of hexane and 3 ml of distilled water were
added and shaken to ensure complete mixing. Appropriate aliquots of
the hexane layerwere evaporated under nitrogen andused for cholesterol
measurement. HPLC analysis was made using aWaters Bondapak C18
10m reversed-phase column (30 cm 4mm inner diameter), with the
mobile phase being 2-propanol/acetonitrile (50:50, v/v) and the flow rate
of 1 ml/min. The amount of cholesterol was calculated from standard
curves and the identity of the peaks was confirmed by spiking the sample
with known standards.
Preparation of A peptides.Human recombinant A1–42 andA42–1
peptides (Bachem) were dissolved to 1 mM in hexafluoroisopropanol
(HFIP) and aliquoted into microcentrifuge tubes, then the HFIP was
evaporated, and the peptides were stored at 20°C until use. For oligo-
meric assembly, concentrated peptides were resuspended in DMSO (5
mM) and then diluted to 100M in phenol red-free media and incubated
at 4°C for 24 h. Western blot analysis demonstrated the presence of
soluble oligomeric forms of A (supplemental Fig. S1, available at
www.jneurosci.org as supplemental material).
A infusion. The infusion model was adopted from previous work on
the rat infusion model (Frautschy et al., 1996). Briefly, stainless steel
cannula attached to micro-osmotic pumps (model 1004, Alzet) were
stereotaxically implanted into the right lateral cerebral ventricle (at co-
ordinates 1.0 mm mediolateral and 0.5 mm anterioposterior from
bregma; 2 mm dorsal-ventral from skull). Pumps contained either
oligomeric human A1–42 (0.45g/l) in vehicle [4mMHEPES pH 8.0
 0.21 g/l human high-density lipoprotein (HDL)] or vehicle alone.
HDL was used in the pump to reduce A aggregation and enhance neu-
ropil delivery. The pump contents were released over a period of 28 d at
a rate of0.11l/h (50 ng/hA; 26 ng/hHDL), which corresponds to 36
pmol/g brain/h. ELISA analyses indicated that the human recombinant
A content found in the brain after this infusion period was 4.3  0.6
ng/g, which is in the range of the levels found in transgenic mice and
humans (Hsiao et al., 1996; Pirttila¨ et al., 1997). At postoperative day 28,
mice were anesthetized and perfused with PBS buffer containing a pro-
tease inhibitor cocktail. The brains were then removed and longitudi-
nally bisected. The right half of the brain was fixed and embedded for
histological examination, while the left hemisphere was snap frozen for
biochemical evaluation. Levels of endogenous or human recombinant
A1–42 peptide in brain extracts were determined with duplicate mea-
surements by the A1–42 ELISA kits from Biosource International, ac-
cording to the manufacturer’s instructions. In some cases, GSH ethyl
ester was either added to the infusion solution (0.5 mmol/ml) as de-
scribed previously (Zeevalk et al., 2007), or injected intraperitoneally
(1.25 mmol/kg/d) every 12 h over the last 2 weeks of the infusion period
as described previously (Mårtensson et al., 1993) to test its efficacy in the
protection against A-mediated neuroinflammation and injury.
Immunohistochemistry. Cryopreserved sections (10 m) from –1.2
mm through –2.4 mm from bregma were processed according to the
avidin–biotin–peroxidase (ABC, Vectastain; Vector Laboratories) stain-
ing method. After antigen retrieval treatment, the endogenous peroxi-
dase was blocked by exposure to 2% H2O2 in methanol for 30 min. The
sections were treated with the Avidin/Biotin blocking kit from Vector
Laboratories according to the manufacturer’s instructions. The primary
antibodies: mouse anti-A (1:300, Sigma), rabbit anti-GFAP (1:500,
Dako), and rat anti-F4/80 (1:200, Santa Cruz Biotechnology) were incu-
bated overnight at 4°C. After washing with PBS, sections were then incu-
bated for 1 h with appropriated biotinylated secondary antibodies at a
dilution of 1:400, followed by ABC staining for 1 h. The immunoreaction
was visualized with diaminobenzidine (DAB enhanced liquid substrate
system, Sigma). Sections were counterstained with hematoxylin (Dako).
Immunofluorescence and laser confocal imaging. Cortical neurons were
fixed for 15 min with 3.7% paraformaldehyde before permeabilization
with 0.1% saponin in blocking buffer (1%BSA 20mMGlycine in PBS)
for 15 min. Then, cells were incubated in the presence of anti-
cytochrome cmonoclonal antibody (1:200, clone 6H2.B4; PharMingen)
diluted in blocking buffer with 0.025% saponin for 1 h at 37°C after 45
min incubation with the secondary antibody, FITC-conjugated goat
anti-mouse IgG (1:400, Caltag Laboratories). Filipin (50 mg/ml, Sigma)
was added during the secondary antibody incubation. Dewaxed hip-
pocampal sections were first boiled in citrate buffer (10 mM sodium
citrate pH6.0) and incubatedwith 0.1 M glycine/PBS for 20min to reduce
autofluorescence. Tissues processed for A staining were pretreated with
99% formic acid for 7min. The sections were incubated overnight at 4°C
with monoclonal anti-A1–42 (1:300, Sigma) rabbit anti-cytochrome c
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(1:100, Santa Cruz Biotech), rat anti-F4/80 (1:200, Santa Cruz Biotech-
nology), and rabbit anti-GFAP (1:500, Dako) antibodies diluted in anti-
body diluent with background-reducing components from Dako. After
washing in PBS, the sections were incubated for 45 min with the second-
ary antibodies diluted in the same vehicle solution. The secondary anti-
bodies used were: FITC-conjugated goat anti-mouse IgG (1:400, Caltag
Laboratories), Cy3-conjugated anti-rabbit IgG (1:400, Jackson Immu-
noResearch), and Cy3-conjugated anti-rat IgG (1:400, Jackson Immu-
noResearch). In some cases, nuclei were stained with Hoechst 33258 (2
g/ml) before mounting the samples in Fluoromount-G (Southern Bio-
technology). Confocal images were collected using a Leica SP2 laser scan-
ning confocal microscope equipped with UV excitation, an argon laser, a
633/1.32 OIL PH3 CS objective and a confocal pinhole set at 1 Airy unit.
All the confocal images shown were single optical sections.
Caspase-3 activity and mitochondrial membrane potential (m).
Caspase activation in cell extracts was determined spectrofluorometri-
cally using the specific fluorescent substrate Ac-DEVD-AMC (100 M,
Bachem). The release of 7-amino-4-trifluoromethyl coumarin (AMC)
was continuously recordedwith excitation at 355 nmand emission at 460
nm. The mitochondrial membrane potential was measured using tetra-
methylrhodamine ethyl ester (TMRE, 50 nM). The dye retention was
analyzed with a Becton-Dickinson FACScan flow cytometer in FL2.
Electronmicroscopy. Pellets containing themitochondria purified frac-
tion were fixed in 3% glutaraldehyde, 10 mM sodium phosphate buffer,
pH 7.2, postfixed in 1% osmium tetroxide, dehydrated in graded steps of
ethanol through propylene oxide, and embedded in Spurr (Sigma). Fi-
nally, ultrathin sections were stained with uranyl acetate and lead citrate
and photographed in a JEOL JEM 1010 electron microscope.
Statistics. Results are expressed as means SD. Statistical significance
was performed using an ANOVA followed by Dunnett’s post hoc tests for
multiple comparisons or by the unpaired two-tailed Student’s t test as
indicated in the figure legends. A p	 0.05 value was considered statisti-
cally significant.
Results
Tg-SREBP-2 mice exhibit brain mitochondrial cholesterol
accumulation, mGSH depletion, and enhanced susceptibility
to A neurotoxicity
To examine whether brain mitochondrial cholesterol modulates
A toxicitywe used transgenicmice overexpressing the truncated
active form of the transcription factor SREBP-2 (Tg-SREBP-2),
which controls cholesterol synthesis (Horton et al., 2002). We
first assessed whether Tg-SREBP-2 mice displays the cholesterol
accumulation in brain which has been reported in liver and adi-
pose tissue (Horton et al., 1998). The quality of brain mitochon-
dria from Tg-SREBP-2 mice was assessed by electron micros-
copy, and lack of contamination from endoplasmic reticulum,
plasma membrane and endosomes was estimated from Western
blot analysis of PERK, Na/K ATPase 1, and Rab5A, respec-
tively (supplemental Fig. S2, available at www.jneurosci.org as
supplemental material). Biochemical analyses indicated en-
hanced cholesterol levels in the homogenate and mitochondrial
fraction of Tg-SREBP-2 mice with respect to wild-type (WT)
mice (Fig. 1A). mGSH is a critical mitochondrial antioxidant,
which is negatively regulated by cholesterol accumulation due to
impaired transport of cytosol GSH into mitochondria via mod-
ulation of membrane dynamics (Colell et al., 1997; Marí et al.,
2006). Mitochondria from Tg-SREBP-2 mice exhibited lower
mGSH levels comparedwithwild-typemice, whereas the content
of GSH in the homogenate remained unaffected (Fig. 1A). Next,
we evaluated the mitochondrial response to A-mediated oxida-
tive stress. Soluble oligomeric A1–42 (1 M for 2 h) induced a
2-fold higher DCF (2
,7
-dichlorodihydrofluorescein) fluores-
cence, reflecting ROS generation in mitochondria from Tg-
SREBP-2 mice compared with wild-type mice (Fig. 1B), which
was accompanied by enhanced release of cytochrome c and Smac/
Figure 1. Increased susceptibility to A1–42 exposure of brain mitochondria and cortical
neurons from SREBP-2 transgenic mice. A, Total cholesterol levels and GSH levels of brain ho-
mogenate (Homo.) and isolated mitochondria (Mit.) from WT and SREBP-2 transgenic (Tg)
mice; *p	 0.05 (n 6–8 per genotype).B, C, WT and transgenic (TgSREBP-2)mitochondria
(1 mg/ml) were exposed to A1–42 (1M) for 2 h. B, Hydrogen peroxide generation deter-
mined by DCF fluorescence (A.U.: arbitrary units). *p 	 0.05, **p 	 0.01 (n  6–8 per
genotype). C, After A treatment mitochondria were pelleted and the resulting supernatants
(Spnt) and pellets were analyzed for the presence of apoptogenic proteins. Shown are
representative immunoblottings of cytochrome c (Cyt C) and Smac/DIABLO (n 4). D, E,
Primary neurons isolated from WT and transgenic (TgSREBP-2) cerebral cortices at 6 DIV.
D, Representative confocal images of cortical neurons stained with filipin (red) andmouse
anti-cytochrome c antibody followed by the appropriated FITC-conjugated secondary an-
tibody (Cyt C, green). Scale bar: 10m. E, Cell death of cortical neurons after exposure to
increasing doses of A1– 42 as indicated for 48 h. *p	 0.05 versus untreated cells (0 nM),
# p	 0.01 versus WT cells (n 4 – 6). Values are mean SD; mean differences were
compared by unpaired Student’s t test.
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DIABLO (Fig. 1C). To further assess whether the increased sen-
sitivity of isolated mitochondria to A-induced oxidative stress
impacts on neuronal death, we isolated cortical neurons from
wild-type and Tg-SREBP-2 embryos followed by A exposure.
Immunostaining analyses using the neuronal marker
microtubule-associated protein 2 (MAP-2) confirmed the
neuronal-enrichment of the cultures (supplemental Fig. S3,
available at www.jneurosci.org as supplemental material). Laser
confocal microscopy indicated higher cholesterol levels in corti-
cal neurons from Tg-SREBP-2 mice compared with wild-type
mice revealed by staining with filipin, a fluorescent polyene anti-
biotic that binds specifically to the 3-hydroxyl group of sterols
(Norman et al., 1972; Marí et al., 2006), which extensively colocal-
ized with mitochondria stained with cytochrome c antibody (Fig.
1D). These findings were accompanied by lower GSH levels in mi-
tochondria isolated from cortical neurons of Tg-SREBP-2 mice
compared with wild-type mice (2.1  0.4 vs 3.3  0.5 nmol/mg
protein), with the sparing of cytosol GSH content (data not shown).
Finally, cortical neurons from Tg-SREBP-2 mice exhibited en-
hanced susceptibility to A1–42 (0.5 nM-1 M for 48 h) mediated
cell death compared with that of wild-type mice (Fig. 1E). Impor-
tantly, this sensitivity in Tg-SREBP-2 mice is observed at a concen-
tration of A1–42 as low as 5 nM.
Sensitivity of brain mitochondria fromNPC1/mice to A-
induced oxidative stress and release of proapoptotic proteins
NPC1 is a late endosomal protein involved in the intracellular
transport of cholesterol, whose ablation results in cholesterol and
sphingolipids loading and progressive neurodegeneration (Paul
et al., 2004). Recently, elevated mitochondrial cholesterol levels
and mitochondrial dysfunction has been reported in the liver
(Marí et al., 2006) and brain (Yu et al., 2005) from NPC1/
mice. Cholesterol contentwas higher in brainmitochondria from
NPC1/ mice compared with wild-type mice (Fig. 2A), which
was accompanied by 50–60% depletion of mGSH stores (Fig.
2A), without changes in cytosol GSH (data not shown). To ex-
amine the susceptibility of brain mitochondria from NPC1/
mice to oligomeric A, we first determined the generation of
mitochondrial ROS after exposure to A 1–42 (1M for 2 h). As
seen, DCF fluorescence in response to A was higher in brain
mitochondria from NPC1/ mice compared with mitochon-
dria from NPC1/ brain (Fig. 2B). Moreover, A incubation
induced an enhanced release of cytochrome c and Smac/DIABLO
in mitochondria from NPC1/mice (Fig. 2C). Collectively the
preceding findings in Tg-SREBP-2 andNPC1/mice reveal the
correlation between mitochondrial cholesterol loading and sus-
ceptibility to A-induced oxidative stress and neurotoxicity, ef-
fects that are accompanied by selective mGSH depletion.
mGSH-dependent susceptibility of brain mitochondria to
A toxicity
Early GSH depletion and altered GSH redox cycle have been
recently shown in AD transgenic mice (Resende et al., 2008).
Although GSH levels protect against A neurotoxicity and A
has been shown to stimulate ROS generation frommitochondria
(Cardoso et al., 2001; Boyd-Kimball et al., 2005; Lin and Beal,
2006), however, the particular role of mGSH depletion on A-
mediated toxicity has not been specifically addressed before. To
investigate this question, mitochondria from rat brain were de-
pleted of GSH by ethacrynic acid (EA), which covalently binds to
GSH.As shown, EA (5M for 15min) depletedmGSH levels (Fig.
3A) and enhanced DCF fluorescence by A1–42, indicative of
higher ROS generation (Fig. 3B), an effect not observed when
mitochondria were exposed to the nontoxic peptide A 42–1
(Fig. 3B). A stepwise increase inmitochondrial DCF fluorescence
by A1–42 peptide was observed as a function of mGSH deple-
tion by EA, that was accompanied by enhanced mitochondrial
lipid peroxidation, estimated from the fluorescence loss of cis-
parinaric-stained mitochondria (supplemental Fig. S4A–C,
available at www.jneurosci.org as supplemental material). To
rule out nonspecific effects of EA, we depleted mGSH in vivo
using buthionine sulfoximine (BSO), a specific inhibitor of
-GCS (-glutamylcysteine synthetase), the rate-limiting en-
zyme in GSH biosynthesis (Jain et al., 1991). Brain mitochondria
from BSO-treated rats exhibited mGSH depletion (Fig. 3A), re-
Figure 2. Isolated brain mitochondria from NPC1 knock-out mice show an increased sensi-
tivity to A1–42.A, Total cholesterol levels (white bars) and GSH levels (black bars) of isolated
mitochondria from NPC1/ and NPC1/ brains. *p	 0.05 (n 3–4 per genotype). B,
Hydrogen peroxide generation determined by DCF fluorescence of mitochondria (1 mg/ml)
incubated with A1–42 (1M) for 2 h. *p	 0.05, **p	 0.01 (n 3–4 per genotype). C,
After 2 h treatment with A1–42 (1M)mitochondria were pelleted and the resulting super-
natants (Spnt) and pellets were analyzed byWestern blotting for the presence of cytochrome c
(Cyt C) and Smac/DIABLO. Representative immunoblottings are shown. Values aremean SD;
mean differences were compared by unpaired Student’s t test. prot., Protein; A.U., arbitrary
units.
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capitulating the effects observed with EA on A-induced ROS
generation (Fig. 3B). In addition, mGSH depletion by both strat-
egies enhanced the mitochondrial release of cytochrome c (Fig.
3C) and Smac/DIABLO (data not shown) after exposure to A.
To further analyze the source of ROS induced by A, mitochon-
drial electron flowwas blocked at different respiratory complexes
(Fig. 3D). Inhibition of complex III by antimycin A potentiated
ROS generation by A in GSH-depleted mitochondria, while
preincubation with rotenone and TTFA (thenoyltrifluoroac-
etone), which block complex I and II, respectively, prevented the
A-mediated increase of DCF fluorescence, pointing to complex
III as the major site of ROS generation by A. These findings
indicate that mGSH controls the mitochondrial oxidative stress
generation by A.
Selective mGSH depletion with the spare of cytosol GSH
sensitizes human neuronal and glial cells to A neurotoxicity
We next asked whether selective mGSH depletion modulates A
neurotoxicity. To address this question, human neuroblastoma
SH-SY5Y cells were exposed to 3-hydroxy-4-pentenoate (HP), a
fatty acid derivative which is biotransformed in mitochondria
into a Michael electrophile and then conjugated with GSH, re-
sulting in its depletion (Marí et al., 2006, 2008, García-Ruiz et al.,
2003). As seen, HP decreased mGSH levels with the sparing of
GSH cytosol stores (Fig. 4A), sensitizing SH-SY5Y cells to A-
induced cell death (Fig. 4B). Similar results were observed in
glial-derived H4, C6 and U118 cell lines after selective mGSH
depletion by HP and A challenge (supplemental Fig. S5A,B,
available at www.jneurosci.org as supplemental material), indi-
cating that the role of mGSH in regulating A cytotoxicity is not
restricted to neuronal cells. mGSH depletion in SH-SY6Y cells by
HP potentiated A-induced DCF fluorescence, indicative of en-
hanced ROS generation, and loss of mitochondrial membrane
potential (supplemental Fig. S6A,B, available at www.jneurosci.
org as supplementalmaterial). Dying SH-SY5Y cells afterHPplus
A exposure exhibited apoptotic features, including chromatin
condensation/nuclear fragmentation (Fig. 4C) and increased
caspase-3 activity (Fig. 4D). Interestingly, preincubationwith the
pancaspase inhibitor qVD-OPH (quinoline-Val-Asp-CH2-
difluorophenoxy) prevented the morphological changes in chro-
matin condensation (Fig. 4C) and caspase-3 activation (Fig. 4D)
induced byHPplus A challenge, but failed to protect against cell
death (Fig. 4E). Pretreatment with antioxidants such asN-acetyl-
cysteine (NAC) and butylated hydroxyanisole (BHA) signifi-
cantly decreased ROS generation induced by HP plus A expo-
sure (Fig. 4F) and the combined pretreatment with NAC and
qVD-OPH protected mGSH-depleted SH-SY5Y cells against cell
death triggered by A (Fig. 4E). Overall, these findings indicate
that selective mGSH depletion sensitizes neuronal and glial cells
to A by stimulating oxidant-dependent cell death and caspase-
independent apoptosis.
Neuroinflammation in Tg-SREBP-2 mice after in vivo
infusion of human A
Having shown that brain mitochondrial cholesterol modulates
A toxicity by regulating mGSH, we next evaluated the onset of
pathological features of AD such as neuroinflammation after in-
tracerebroventricular infusion of human A1–42 in Tg-
SREBP-2mice. Staining with an antibody that recognizes human
A (but not the endogenous mouse A) demonstrated diffuse
amyloid deposition in the hippocampus of A-infused mice (for
28 d) (Fig. 5A). Quantitative determination by ELISA revealed
equivalent A loading in wild-type mice and Tg-SREBP-2 mice
Figure3. Mitochondrial GSH regulates A-inducedoxidative stress. Depletion ofmitochon-
drial GSH levels was assessed in vitro by incubation of isolated mitochondria (1 mg/ml) with 5
M ethacrynic acid (EA) for 15 min or in vivo by inhibiting the GSH synthesis with buthionine
sulfoximine treatment (BSO, 3 mmol/kg). A, GSH levels after EA or BSO treatment. *p	 0.05
(n 4–6). B, C, Mitochondria from rat brain pretreated with EA or BSO were exposed to A
1–42 (5M) or the inactive form A 42–1 (5M) for 2 h. B, Hydrogen peroxide generation
determined by DCF fluorescence (A.U.: arbitrary units; NT: untreatedmitochondria). *p	 0.05
(n 4–6). C, After A treatmentmitochondria were pelleted and the resulting supernatants
(spnt) and pellets were analyzed for the presence of cytochrome c (Cyt C) and Smac/DIABLO.
Shown are representative immunoblottings of three independent experiments. D, Effect of
blocking the electron transport chain at complex I, II, or III on the generation of hydrogen
peroxide by A. After EA treatment mitochondria were incubated with rotenone and TTFA
(Rot/TTFA, 20 and 15 M, respectively), antimycin A (Antimyc. A, 5 M), and/or A (5 M)
during 60min. The blockers of the respiratory complexeswere added 15min before exposure to
A. Hydrogen peroxide generation was assessed by DCF fluorescence. *p	 0.05 versus un-
treated mitochondria; #p 	 0.01 versus A-treated mitochondria. (n  3). Values are
mean SD; mean differences were compared by Dunnett’s test. prot., Protein; Ctrl., control.
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(54.2  14.6 and 66  11.2 nmol/mg protein, respectively).
Moreover, confocal analysis showed a significant colocalization
of A with cytochrome c staining (Fig. 5B), indicating that a
fraction of the infused A targeted mitochondria. Of note, en-
dogenous brainA1–42 levelswere similar inWTandTg-SREBP-2
mice (supplemental Fig. S7, available at www.jneurosci.org as sup-
plemental material).
Neuroinflammation, manifested as activated microglia and
astrocytes close toAdepositions, is an invariant characteristic of
AD brain, which plays a key role in the progression of the disease
by further amplifying A generation and neuronal damage
(Heneka and O’Banion, 2007). Greater microglia activation, de-
termined by F4/80 immunostaining, was observed in the hip-
pocampus of Tg-SREBP-2 mice infused with A compared with
vehicle-infused or A-infused wild-type mice (Fig. 5C). Astro-
cyte activation, manifested as GFAP immunoreactivity, was also
elevated in hippocampal regions of A-infused Tg-SREBP-2
mice (Fig. 5C). Moreover, confocal analysis of A-infused Tg-
SREBP-2 brains revealed the presence ofmicroglia and astrocytes
colocalizing with A in amyloid deposits (supplemental Fig. S8,
available at www.jneurosci.org as supplemental material). These
histological analyses were complemented by quantitative mea-
surements of mRNA levels of proinflammatory cytokines such as
TNF- and IL-1. ncreased expression of TNF- and IL-1was
only observed in Tg-SREBP-2 brains infused with A (Fig. 5D).
Thus, Tg-SREBP-2 mice are more susceptible to A-induced
neuroinflammation.
Increased oxidative stress, synaptodendritic degeneration and
neuronal damage in Tg-SREBP-2 mice after A infusion
We next assessed the susceptibility of Tg-SREBP-2 mice to A-
induced oxidative stress and neurodegeneration. Malondialde-
hyde (MDA), an end product of lipid peroxidation, and accumu-
lation of oxidized proteins assessed by carbonyl protein
immunoblotting were significantly higher in the brain of A-
infused Tg-SREBP-2 mice compared with A-infused wild-type
mice, with no signs of oxidative stress detected in brains of
vehicle-infused wild-type or Tg-SREBP-2 mice (Fig. 6A,B). Pre-
vious studies have shown that synaptic injury is an early event in
the progression of AD, which correlates with the severity of cog-
nitive deficits in AD patients (Masliah et al., 1994). As shown, the
levels of the presynaptic protein synaptophysin were significantly
lower in Tg-SREBP-2mice infused with A compared with wild-
typemice or vehicle-infused brains (Fig. 6C), indicating extensive
synaptic loss. In addition, neuronal death and apoptosis esti-
mated by Fluoro-Jade B-positive degenerating neurons and
TUNEL staining, respectively, were higher in Tg-SREBP-2 mice
after intracerebroventricular A infusion compared with wild-
typemice (Fig. 6D,E). These data underscore the susceptibility of
Tg-SREBP-2 mice to A-induced neurodegeneration.
GSH ethyl ester coinfusion restores mGSH and protects
against A-induced neurodegeneration in Tg-SREBP-2 mice
To address whether the exacerbated inflammation and neuronal
death of Tg-SREBP-2 mice after A infusion is promoted by
cholesterol-mediated mGSH depletion, GSH ethyl ester
(GSHee), a membrane-permeable form of GSH, was coinfused
withA. GSHee significantly increased themitochondrial pool of
GSH in Tg-SREBP-2 mice (3.2 0.2 vs 1.4 0.5 nmol/mg pro-
tein), preventing A-induced increase in MDA levels (Fig. 6F)
and protein oxidation estimated by carbonyl protein immunore-
activity (supplemental Fig. S9A, available at www.jneurosci.org
as supplemental material). Moreover, reactive astrogliosis and
Figure 4. Selective depletion of mitochondrial GSH in human neuroblastoma SH-SY5Y cells en-
hances the apoptotic cell death induced by A. Mitochondrial GSH depletion was assessed by incu-
batingcellswith (S)-3-hydroxy-4-pentenoate (HP,5mM) for10min.A, GSH levels. *p0.002 (n
4). Cyt., Cytosol; Mit., mitochondria.B, Cell viability after 24 h incubationwith increasing concentra-
tionsofA1–42.*p	0.01versusHP-treatedcellsat0M,**p0.02versuscontrol (Ctrl.) cells at
0M;n.s.,notsignificant(n4).C,ChromatinmorphologyofcellsexposedtoA1–42(5M,24h)
analyzedbyHoechst-33258 staining.Originalmagnification, 200 (n4).D, Caspase-3 activity of
cell extracts from cells exposed to A1–42 (5M, 24 h) with or without the pancaspase inhibitor
qVD-OPH (20M). *p	 0.05 versus HP-treated cells. (n 3). E, F, After preincubation with the
antioxidant agentsN-acetyl-cysteine (NAC, 3mM) or butylated hydroxyanisole (BHA, 20M) and/or
thecaspase inhibitorqVD-OPH(20M) for2h,mitochondrialGSHwasdepletedbyHPtreatmentand
cells were exposed to A 1–42 (5M). (n 3–4). E, Cell death analyzed by PI staining at 24 h
exposure to A1–42. *p	 0.01. F, Hydrogen peroxide generation after 2 h incubationwith A1–
42. *p	 0.05 (A.U.: arbitrary units). Values are mean SD; mean differences were compared by
Dunnett’s test (B, E, and F ) or unpaired Student’s t test.
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microgliosis, determined by GFAP and F4/80 immunoreactivity,
respectively, were also reduced inTg-SREBP-2micewhenGSHee
was coinfused with A (supplemental Fig. S9B, available at
www.jneurosci.org as supplementalmaterial). This outcome cor-
related with a significant decrease in themRNA expression of the
proinflammatory cytokines TNF- and IL-1 (Fig. 6G). In addi-
tion, neuronal damage, assessed by Fluoro-Jade B staining and
TUNEL assay, in the hippocampal regions of A-infused Tg-
SREBP-2 brains was prevented byGSHee coinfusion (Fig. 6D,E).
We further analyzed whether intraperitoneal administration of
GSHee was therapeutic against A-induced neuroinflammation
and neuronal loss. As seen, intraperitoneal GSHee administra-
tion during the A infusion period significantly increasedmGSH
content (Fig. 7A), attenuatingMDA levels (Fig. 7B) and carbonyl
protein immunoblotting (Fig. 7C), indicative of oxidative stress
induced by A in Tg-SREBP-2 mice. In addition, the enhanced
presence of reactive astrocytes (Fig. 7D) and the upregulated ex-
pression of TNF- (Fig. 7E) observed in A-infused transgenic
mice were significantly prevented by GSHee therapy, which cor-
relates with a significant decrease in neuronal damage (Fig. 7F).
Thus, these data indicate that strategies that boost mGSH such as
GSHee protect against A-induced neurodegeneration.
Enhancedmitochondrial cholesterol loading andmGSH
depletion in APP/PS1 transgenic mice
To address the relevance of the preceding findings in AD, we
examined the mitochondrial cholesterol and GSH content in a
genetic mouse model of AD, namely, APP/PS1 transgenic mice.
Brainmitochondria were isolated from 4-, 7-, and 10-month-old
APP/PS1 transgenic mice. As seen (Fig. 8A), mitochondrial cho-
lesterol levels were unchanged in 4- and 7-month-old transgenic
mice, increasing twice as much in 10-month-old APP/PS1 trans-
genic mice compared with wild-type mice of the same age. As
expected from our findings in Tg-SREBP-2 and NPC1/mice,
themGSH levels decreased only in 10-month-oldAPP/PS1 trans-
genic mice (Fig. 8B). Preceding the mitochondrial cholesterol
loading and the subsequent mGSH depletion, we observed a sig-
nificant generation of A detected by ELISA in 4-month-old
APP/PS1 mice (data not shown). Furthermore, either SREBP-2
mRNA and protein levels were significantly elevated in Tg-APP/
PS1 mice (Fig. 8C,D), indicating that activation of SREBP-2 may
contribute to the increase in cholesterol content. Thus, these
findings lend further support for the relevance of enhanced mi-
tochondrial cholesterol levels in AD.
Discussion
Epidemiological, genetic and biochemical studies have identified
cholesterol, A andmitochondria as key factors in ADpathogen-
esis, but the specific relationship of this triad has not been ad-
dressed before. In particular, the role of cholesterol in AD exam-
ined thus far has been limited to the amyloidogenic processing of
APP at the plasma membrane to generate A. In this regard,
varying proportions of the presenilins and other components of
the-secretase complex (nicastrin, Aph-1 and Pen-2), alongwithFigure5. Increasedneuroinflammation in SREBP-2 transgenicmice after A1–42 infusion.
WT and SREBP-2 transgenic (TgSREBP-2) mice were subjected to continuous intracerebroven-
tricular infusion of vehicle or human A1–42 solution (1.2 g/d) for 28 d; then, half of the
brainwas processed for immunohistochemistry and the other hemisphere used for biochemical
analysis.n6–8miceper group.A, A1–42 immunohistochemical staining. Representative
photomicrographs of hippocampus from WT and transgenic mice after infusion are shown.
Scale bar: 100m.B, Confocal analysis of A internalization. Shownare representative images
of A1–24 (green) and cytochrome c (red) immunofluorescence from hippocampal sections of
TgSREBP-2 brains after the infusion period.Merged image indicates partial colocalization of A
with themitochondrial marker cytochrome c (Cyt C, yellow). Nuclei were stainedwith Hoechst-
33258 (shown only in merged image; blue). Scale bar: 10m. C, Activation of microglia and
4
astrocytes analyzed by F4/80 and GFAP immunostaining, respectively. Shown are representa-
tive photomicrographs of F4/80 and GFAP immunoreactivity as indicated, in sections of hip-
pocampus from infused WT and SREBP-2 transgenic (Tg) mice. Scale bar: 100m. D, TNF-
and IL-1mRNA expression analyzed by real-time PCR from WT and SREBP-2 transgenic (Tg)
brain after vehicle or A infusion. Shown are relative values after normalization against 18 s
expression and are representative of three experiments  SD, *p 	 0.01 versus vehicle-
infused TgSREBP-2 mice. Mean differences were compared by unpaired Student’s t test.
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-secretase activity and the -secretase BACE1, are present in
detergent-resistant cholesterol-enriched lipid rafts (Taylor and
Hooper, 2007). In addition, the activities of BACE1 and
-secretase are stimulated by rafts lipid components, such as gly-
cosphingolipids and cholesterol (Kalvodova et al., 2005; Ariga et
al., 2008; Osenkowski et al., 2008). Intriguingly, although the
presence of APP in detergent-resistant rafts is relatively minor
(Lee et al., 1998), once localized to the raft,
the APP may be rapidly cleaved by - and
-secretases, thus contributing to A gen-
eration. Moreover, previous studies have
shown that cholesteryl-ester levels directly
correlate with A production (Puglielli et
al., 2001) and that statins inhibit the
dimerization of -secretase via both
isoprenoid- and cholesterol-mediated
mechanisms (Parsons et al., 2006).
In the current study, we examined the
role of cholesterol in AD from an unusual
perspective and provide evidence linking
mitochondrial cholesterol to A neuro-
toxicity, consistent with and expanding
the recognized role of mitochondrial dys-
function in AD (Casley et al., 2002; Lust-
bader et al., 2004; Caspersen et al., 2005;
Lin and Beal, 2006; Manczak et al., 2006).
In addition to being targets of A toxicity,
it is conceivable that mitochondria may
constitute an additional source of A gen-
eration, in agreement with the presence of
APP inmitochondria fromAD-vulnerable
brain regions (Devi et al., 2006), and the
finding of functional complexes of APP
with -secretase and IDE in mitochondria
(Hansson et al., 2004; Leissring et al.,
2004), arguing that these organelles may
contribute to the amyloidogenic APP pro-
cessing and hence A generation. Regard-
less of the source of A generation either
via the more established pathway of APP
processing at the plasma membrane, par-
ticularly in cholesterol-enriched domains,
or its in situ generation in mitochondria,
we provide evidence that mitochondrial
cholesterol accumulation stands as a criti-
cal determinant of A toxicity both in vitro
and in vivo using Tg-SREBP-2 and
NPC1/mice.
It has been described that SREBP-2
downregulates the expression of genes
which control brain A clearance, such as
LDLR-related protein 1 (also known as
LRP) (Deane et al., 2004). Moreover, re-
cent studies in AD patients and twomouse
models of AD show that overexpression of
serum response factor and myocardin in
cerebral vascular smooth muscle cells
(VSMC) generates an A nonclearing
VSMC phenotype through transactivation
of SREBP-2, which is associated with A
accumulation (Bell et al., 2009); thus, it is
conceivable that Tg-SREBP-2 may exhibit
increased brain A content secondary to
lower LRP1 expression. Althoughwe did not examine the expres-
sion level of LRP1, we did observe that the content of endogenous
A was similar in WT and Tg-SREBP-2 mice. These unexpected
findings are consistent with evidence indicating that LRP1 pro-
motes APP endocytosis and its processing to A production
(Ulery et al., 2000; Zerbinatti et al., 2004).
In agreement with the downregulation of mGSH by increased
Figure 6. A-infused TgSREBP-2 mice display enhanced oxidative stress and neuronal damage which is prevented by GSH
ethyl ester (GSHee) coinfusion. WT and TgSREBP-2 mice were subjected to continuous infusion of vehicle or human A1–42
solution (1.2g/d) for 28 d. n 6–8mice per group.A, Lipid peroxidation estimated as production ofmalondialdehyde (MDA).
*p	 0.03. B, Representative immunoblotting showing presence of carbonyl proteins in WT and TgSREBP-2 (Tg) brains after
infusion. C, Representative immunoblotting showing synaptophysin (Synapt.) protein levels after infusion. Densitometric values
of the bands representing synaptophysin immunoreactivitywere normalizedwith the values of the corresponding-actin bands
(O.D.: normalized optical density). D, Representative images of degenerated neurons in hippocampal regions by Fluoro-Jade B
staining. Scale bar: 50m. E, Representative images of apoptotic cells in hippocampus by terminal deoxynucleotidyl transferase-
mediated nick-end labeling. Scale bar: 25m. F, Lipid peroxidation in infused TgSREBP-2 brains estimated as malondialdehyde
levels (MDA). *p	 0.01 (n 6). G, TNF- and IL-1 mRNA expression analyzed by real-time PCR from infused TgSREBP-2
brains. Relative values were normalized against 18 s expression. *p	 0.05, **p	 0.01 (n 6). Values are mean SD; mean
differences were compared by unpaired Student’s t test.
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cholesterol-mediated impairment of
mGSH transport from cytosol (Marí et al.,
2006, 2008; Colell et al., 1997), we ob-
served that isolated mitochondria from
both Tg-SREBP-2 mice and NPC1 knock-
out mice exhibit mGSH depletion and en-
hanced susceptibility to A-mediated tox-
icity and mitochondrial membrane
permeabilization. Although GSH exists in
both cytosol and mitochondria, this latter
pool has been shown to control the suscep-
tibility to stimuli that trigger mitochon-
drial oxidative stress includingTNF, Fas or
hypoxia (Marí et al., 2006, 2008; Colell et
al., 1997; Lluis et al., 2007). However, al-
though total GSH depletion and altered
GSH redox cycle has been described inAD,
the particular pool of mGSH in modulat-
ing A toxicity has not been specifically
addressed. Two lines of evidence indicate
that the mGSH depletion specifically ac-
counted for the increased susceptibility to
A observed in these geneticmodels. First,
the sensitivity of rat brainmitochondria to
A-mediated oxidative stress and release
of intermembrane apoptotic proteins was
dependent on the levels ofmGSH. Second,
selective pharmacological depletion of
mGSH with the spare of cytosol GSH in
human neuroblastoma and glial cells sen-
sitized to A-mediated cell death. Hence
these findings expand the role of choles-
terol in A neurotoxicity, indicating that
in addition to fostering the amyloidogenic
processing of APP, mitochondrial choles-
terol modulates A neurotoxicity via
mGSH regulation. Interestingly, recent
findings have shown that hydrogen perox-
ide promotes A production through
JNK-dependent activation of -secretase
(Shen et al., 2008), implying that in addi-
tion to the modulation of A toxicity, en-
hanced mitochondrial cholesterol-
mediated mGSH depletion may activate
an autoamplification loop by stimulating
oxidative stress to further generate A,
thus establishing a toxic vicious cycle.
Although increased cholesterol levels
have been described in membranes from
brain tissue samples of AD patients (Cutler et al., 2004; Bandaru
et al., 2007), the specific pool of mitochondrial cholesterol has
not been previously reported to the best of our knowledge. How-
ever, enhanced immunocytochemical localization of steroidege-
nic acute regulatory protein (StAR) has been described in the
pyramidal hippocampal neurons of AD-affected patients (Web-
ber et al., 2006). Given the role of StAR in the mitochondrial
transport of cholesterol (Soccio and Breslow, 2004) and hence in
the modulation of mitochondrial cholesterol levels (Montero et
al., 2008), the increased expression of StAR inADpatients, would
strongly suggest that mitochondrial cholesterol accumulation
may actually occur in patients with AD. Indeed, in the current
study, we observedmitochondrial cholesterol loading and subse-
quent mGSH depletion in APP/PS1 transgenic mice, a genetic
mouse model of AD, and interestingly, these changes in mito-
chondria were preceded byA accumulation in the brain of APP/
PS1 mice. Based on this temporal relationship, it is tempting to
speculate that A may regulate cholesterol homeostasis and/or
trafficking. Although this needs to be specifically addressed, con-
sistent with this possibility, previous studies underscored that A
1–40/1–42 ratio altered lipid homeostasis, and that familial pre-
senilin mutations decreased the A1–40/1–42 ratio resulting in
enhanced cholesterol levels (Grimm et al., 2005), suggesting that
A generation contributed to increased cholesterol content. A
complication in this possible scenario of mutual regulation be-
tween cholesterol and A is the observation that cholesteryl-
esters unlike free cholesterol modulated A generation (Puglielli
et al., 2001).
Figure 7. GSH ethyl ester (GSHee) intraperitoneal therapy protects against A-induced neurodegeneration in Tg-SREBP-2
mice. WT and TgSREBP-2mice were subjected to continuous infusion of human A1–42 solution (1.2g/d) for 28 d. GSH ethyl
ester (1.25mmol/kg/d) or vehicle alonewere administered intraperitoneally over the last 2week of the infusion period.n4–6
mice per group. A, Mitochondrial GSH levels. *p 0.01. prot., Protein. B, Lipid peroxidation estimated as production of malon-
dialdehyde (MDA). *p	 0.01. C, Representative immunoblotting showing presence of carbonyl proteins. D, Activation of astro-
cytes analyzed by GFAP immunostaining. Shown are representative photomicrographs GFAP immunoreactivity in hippocampal
sections. Scale bar: 100m. E, TNF- expression analyzed by real-time PCR. Relative values were normalized against 18 s expression.
*p	 0.05. F, Representative images of apoptotic cells in hippocampus by terminal deoxynucleotidyl transferase-mediated nick-end
labeling. Scale bar: 25m.Values aremean SD;meandifferenceswere compared by unpaired Student’s t test.
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Previous studies described the requirement for functional mi-
tochondria in A-mediated neurotoxicity and that A interacts
with the regulatory heme of complex IV leading tomitochondrial
dysfunction and ROS production (Cardoso et al., 2001; Atamna
and Boyle, 2006). Through inhibition of electron flow at different
mitochondrial respiratory complexes, we show that complex III
is a major site for mitochondrial ROS by A, whose levels in-
creased if mGSH levels are low, resulting in mitochondrial depo-
larization, release of cytochrome c, and caspase-3 activation. In-
terestingly caspase inhibition failed to protect mGSH-dependent
sensitization of SH-SY5Y cells to A-mediated cell death despite
efficiently preventing the acquisition of apoptotic features, sug-
gesting that A stimulated both an oxidant-dependent cell death
pathway and caspase-independent apoptosis pathways, which are
modulated by mGSH levels.
Our in vivo studies underscore a higher sensitivity of Tg-
SREBP-2 mice to infusion of human A, resulting in enhanced
lipid peroxidation, oxidative modification of proteins, glia acti-
vation, indicative of neuroinflammation, and neuronal damage.
Although cholesterol upregulation in Tg-SREBP-2 did not mod-
ulate endogenous A generation, we observed that a significant
fraction of infused human A colocalized with mitochondria,
pointing to themitochondria as a target of the A toxicity in vivo.
To substantiate that the increased susceptibility of Tg-SREBP-2
mice to in vivo A infusion was mediated by mitochondrial
cholesterol-induced mGSH depletion, we tested the role of coin-
fusing A with GSH ethyl ester. GSH ethyl ester is a membrane
permeable form of GSH, which unlike GSH precursors such as
N-acetylcysteine increases mGSH independently of the transport
of GSH into mitochondria (Marí et al., 2006, 2008). This implies
that GSH ethyl ester bypasses the block of cytosol GSH transport
into mitochondria imposed by cholesterol-mediated membrane
dynamics, thus leading to mGSH replenishment (Marí et al.,
2006, 2008; Colell et al., 1997). The downregulation of oxidative
stress, neuroinflammation and protection against in vivo infu-
sion of A in Tg-SREBP-2 via mGSH recovery highlights the
relevance of mitochondrial cholesterol-mediated regulation of
mGSH in A-induced neurodegeneration. From a therapeutical
perspective, the fact that the particular pool ofmGSH rather than
cytosol GSH determines A susceptibility implies that efforts
should focus to specifically replenishmGSH to slowdowndisease
progression. The therapeutic usefulness of this strategy is illus-
trated here by the ability of intraperitoneal administration of
GSH ethyl ester in protecting against A-induced neuroinflam-
mation and neuronal loss. In addition to directly modulating
mGSH by GSH ethyl ester, targeting the increased pool of mito-
chondrial cholesterol may be of relevance in AD, as it would be
expected to restore mGSH levels. In line with this possibility, it
was shown in obese ob/ob mice that atorvastatin therapy was
useful in preventing susceptibility to TNF-mediated steatohepa-
titis by preventing mitochondrial cholesterol loading which sub-
sequently resulted in increased mGSH levels (Marí et al., 2006).
Taking this precedent as well as the previous suggestions for the
use of statins in AD (Wolozin et al., 2000; Fassbender et al., 2001;
Parsons et al., 2006), the therapeutic combination of statins plus
GSH ethyl ester may be of potential therapeutic significance in
AD.
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